Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.
COPD
Depression
PHQ-9
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
17
12
2018
accepted:
04
02
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
The diagnosis of depression, a frequent comorbidity of chronic obstructive pulmonary disease (COPD), is often supported by questionnaires, such as the Patient Health Questionnaire 9 (PHQ-9). It is unknown to which extent its single questions are affected by the clinical characteristics of COPD patients.We addressed this question in 2255 GOLD grade 1-4 patients from the COSYCONET (COPD and Systemic Consequences - Comorbidities Network) COPD cohort. The dependence on COPD severity was assessed using symptoms, exacerbation risk (GOLD A-D; modified Medical Research Council dyspnoea scale (mMRC)), and frequent comorbidities as predictors of PHQ-9 results, while including age, gender, body mass index (BMI) and smoking habits as covariates.Symptoms and exacerbation risk were associated with depression in an additive manner, with mean elevations in the PHQ-9 sum score by 2.75 and 1.44 points, respectively. Asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases by 0.8 to 1.3 points. Overall, the COPD characteristics contributed to the mean PHQ-9 score by increases from 4.5 or 5.2 to 6.3 points, respectively, when either taking GOLD A as reference or the absence of comorbidities. This finding was independent of the diagnosis of mental disorder or the intake of antidepressants. The presence of COPD led to an increase in the proportion of scores indicating depression from 12 to 22%. Single item analysis revealed homogenous effects regarding GOLD groups, but heterogeneous effects regarding GOLD grades.These findings indicate specific effects of COPD severity on the PHQ-9 depression score, especially symptoms and exacerbation risk, explaining the high prevalence of depression in COPD. Alternative explanations like an overlap of COPD severity and PHQ-9 items are discussed. Of note, we also found COPD treatment effects on depression scores.
Identifiants
pubmed: 30744630
doi: 10.1186/s12931-019-0997-y
pii: 10.1186/s12931-019-0997-y
pmc: PMC6371561
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Subventions
Organisme : German Federal Ministry of Education and Research
ID : 01 GI 0881
Organisme : AstraZeneca GmbH
ID : not applicable
Organisme : Bayer Schering Pharma AG
ID : not applicable
Organisme : Boehringer Ingelheim Pharma GmbH & Co. KG
ID : not applicable
Organisme : Chiesi GmbH
ID : not applicable
Organisme : GlaxoSmithKline
ID : not applicable
Organisme : Grifols Deutschland GmbH
ID : not applicable
Organisme : MSD Sharp & Dohme GmbH
ID : not applicable
Organisme : Mundipharma GmbH
ID : not applicable
Organisme : Novartis Deutschland GmbH
ID : not applicable
Organisme : Pfizer Pharma GmbH
ID : not applicable
Organisme : Takeda Pharma Vertrieb GmbH & Co
ID : not applicable
Références
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Psychosomatics. 2006 Jan-Feb;47(1):62-7
pubmed: 16384809
Fam Pract. 2007 Jun;24(3):217-23
pubmed: 17504776
BMJ. 2009 Mar 19;338:b750
pubmed: 19299475
Eur Respir J. 2009 May;33(5):1165-85
pubmed: 19407051
Psychiatry (Edgmont). 2009 Jan;6(1):38-51
pubmed: 19724742
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Gen Hosp Psychiatry. 2011 May-Jun;33(3):217-23
pubmed: 21601717
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Chest. 2013 Sep;144(3):766-777
pubmed: 23429910
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):733-9
pubmed: 23703492
Dtsch Arztebl Int. 2013 Jun;110(23-24):413-9
pubmed: 23837086
J Korean Med Sci. 2013 Jul;28(7):1048-54
pubmed: 23853488
Eur Respir J. 2014 Sep;44(3):734-43
pubmed: 24876171
Addict Behav. 2014 Oct;39(10):1418-29
pubmed: 24935795
Eur Respir Rev. 2014 Sep;23(133):345-9
pubmed: 25176970
J Affect Disord. 2015 Jan 1;170:138-42
pubmed: 25240840
Int J Chron Obstruct Pulmon Dis. 2014 Dec 04;10:1321-9
pubmed: 25587219
Curr Opin Pulm Med. 2016 Mar;22(2):125-9
pubmed: 26814143
Respir Med. 2016 May;114:27-37
pubmed: 27109808
BMC Pulm Med. 2016 May 10;16(1):70
pubmed: 27160582
Respir Res. 2016 Jul 12;17(1):81
pubmed: 27405652
Respir Med. 2016 Aug;117:154-61
pubmed: 27492526
J Am Geriatr Soc. 2016 Nov;64(11):e201-e206
pubmed: 27783384
PLoS One. 2016 Oct 28;11(10):e0163408
pubmed: 27792735
Respirology. 2017 Apr;22(3):575-601
pubmed: 28150362
J Clin Diagn Res. 2017 Feb;11(2):OC24-OC27
pubmed: 28384911
Medicine (Baltimore). 2017 May;96(19):e6836
pubmed: 28489768
Psychiatry Investig. 2017 May;14(3):306-313
pubmed: 28539949
J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24
pubmed: 29169740
Respir Med. 2018 Jan;134:79-85
pubmed: 29413512
Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605
pubmed: 30282573